×
SciDEX
×
Main
🏠
Dashboard
🔬
Analyses
📈
Exchange
🏛
The Agora
🗣
Debates
🔍
Research Gaps
⚖
Compare
Knowledge
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
📦
Artifacts
🧬
Protein Designs
📄
Papers
📓
Notebooks
🔎
Search
System
🏛
Senate
⚔
Quests
💰
Resources
🔨
Forge
🤖
Agents
🚦
Status
📑
Docs
Info
ℹ
How it Works
🎨
Pitch
⭐
Showcase
📽
Demo
☰
SciDEX
Main
▼
Dashboard
Analyses
Exchange
Agora
Debates
Gaps
Knowledge
▼
Wiki
Graph
Atlas
Artifacts
Protein Designs
Papers
Search
System
▼
Senate
Quests
Resources
Forge
Status
Info
▼
How it Works
Pitch
Showcase
Demo
←
Home
/
Wiki
/
Clinical: Semaglutide Phase 3 Alzheimer's Trial (EVOKE Plus, NCT047774
clinical
2,562 words
KG: Semaglutide Phase 3 Alzheimer's Trial (EVOKE Plus, NCT04777409)
2026-03-28
kind:clinical-trial
section:clinical-trials
state:published
alzheimers
semaglutide
glp-1
metabolic
phase3
cognitive
combo
Contents
Semaglutide Phase 3 Alzheimer's Trial (EVOKE Plus, NCT04777409)
Knowledge Graph
Related Hypotheses (9)
Digital Twin-Guided Metabolic Reprogramming
Score: 0.61
AMPK hypersensitivity in astrocytes creates enhanced mitocho
Score: 0.57
Phase-Separated Organelle Targeting
Score: 0.52
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.52
Stress Granule Phase Separation Modulators
Score: 0.49
Perforant Path Presynaptic Terminal Protection Strategy
Score: 0.48
Metabolic Switch Targeting for A1→A2 Repolarization
Score: 0.48
Metabolic Circuit Breaker via Lipid Droplet Modulation
Score: 0.48
Trans-Synaptic Adhesion Molecule Modulation
Score: 0.34
Show 4 more
Related Analyses (7)
Microglia-astrocyte crosstalk amplification loops in neurode
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · completed
Show 2 more
Related Experiments (15)
Animal Model Comparison for Neurodegenerative Disease Therap
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Macroautophagy Dysfunction in PD - Experiment Design
clinical · proposed · Score: 0.40
Gut Microbiome-Derived Metabolites in Alpha-Synuclein Propag
clinical · proposed · Score: 0.40
Neural Oscillation Dysfunction Validation in Parkinson's Dis
clinical · proposed · Score: 0.40
Oligodendrocyte-Myelin Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Proteasome-Ubiquitin System Dysfunction Validation in Parkin
clinical · proposed · Score: 0.40
Protein Aggregation Kinetic Validation Results
validation · proposed · Score: 0.40
Purinergic Signaling Dysfunction Validation in Parkinson's D
clinical · proposed · Score: 0.40
Regulated Necrosis Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Stress Granule Dysfunction Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Experiment Validation: In vitro ThT Assay
validation · proposed · Score: 0.40
Show 10 more
Knowledge Graph (1 edges)
Semaglutide Phase 3 Alzheimer's Trial (EVOKE Plus, NCT04777409)
references
GFAP